# NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

> **NCT03589339** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Nanobiotix** · enrollment: 145 (estimated)

## Conditions studied

- Radiotherapy
- Immunotherapy
- Microsatellite Instability-High Solid Malignant Tumour
- Metastasis From Malignant Tumor of Liver
- Squamous Cell Carcinoma of Head and Neck
- Metastasis From Malignant Tumor of Cervix
- Metastatic Renal Cell Carcinoma
- Metastasis From Malignant Melanoma of Skin (Disorder)
- Metastatic Triple-Negative Breast Carcinoma
- Metastatic NSCLC
- Metastasis From Malignant Tumor of Bladder (Disorder)

## Interventions

- **DRUG:** NBTXR3
- **RADIATION:** SABR
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03589339
- **Lead sponsor:** Nanobiotix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-16
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589339, "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03589339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*